Eagle Pharmaceuticals Inc (EGRX)

NASDAQ
46.11
-1.10(-2.33%)
After Hours
46.11
0.00(0.00%)
- Real-time Data
  • Volume:
    272,927
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    44.81 - 47.72

EGRX Overview

Prev. Close
47.21
Day's Range
44.81-47.72
Revenue
179.14M
Open
47.08
52 wk Range
36.48-58.25
EPS
0.41
Volume
272,927
Market Cap
595.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
100,350
P/E Ratio
113.88
Beta
0.65
1-Year Change
-9%
Shares Outstanding
12,913,879
Next Earnings Date
Mar 02, 2022
What is your sentiment on Eagle Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Eagle Pharmaceuticals Inc Company Profile

Employees
106

Eagle Pharmaceuticals, Inc. is an integrated pharmaceutical company. The Company takes a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. The Company identifies challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas, as well as in oncology. The Company offers three products: Ryanodex, dantrolene sodium) (Ryanodex), bendamustine ready-to-dilute (RTD) 500ml solution (Belrapzo), and rapidly infused bendamustine RTD (Bendeka). The Company market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. (Teva) markets Bendeka a lyophilized powder formulation of bendamustine hydrochloride in Japan.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellStrong Sell
Technical IndicatorsSellStrong BuyStrong SellStrong SellNeutral
SummaryNeutralNeutralStrong SellStrong SellSell
  • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
    0
    • Two upcoming catalysts: 1) RBC Capital market healthcare on 2/21 and earnings on 2/26 (morning). One of these two days, we may get updates on pending court case against $LLY regarding PEMFEXY.. Floor chatter is that $EGRX will prevail...
      0
      • Rumor is swirling on the trading floor that $EGRX will win the law-suit against $LLY!
        0
        • Erin Consulting downgrades it to SELL with PT $70
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.